Pharming announces agreement with Renova Life targeting factor VIII for the treatment of haemophilia A
20-Dec-2011 -
Pharming Group NV announced that it has signed a service agreement with Renova Life, Inc. The agreement covers the development and supply of founder transgenic rabbits from RLI to Pharming. The founder rabbits will enable Pharming to start the commercial production breeding process. The first ...
hemophilia A
transgenic rabbits